You are here

Award Data

For best search results, use the search terms first and then apply the filters

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. Antibody targeting of ADAM for treatment of triple negative breast cancer

    SBC: Adecto Pharmaceuticals, Inc.            Topic: NCI

    DESCRIPTION provided by applicant Triple negative breast cancers TNBCs account for of breast cancer deaths and lack targeted therapies Drs Sonenshein Mineva and Romagnoli and their co workers recently identified the non essential cell surface protein ADAM A Disintegrin and Metalloprotease as a pivotal promoter of breast tumor growth and metastasis and validated it as a target o ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  2. Inhibitors of the viral nucleoprotein polymerase co factor interaction for human RSV and MPV therapy

    SBC: MICROBIOTIX, INC.            Topic: NIAID

    Human respiratory syncytial virus hRSV and human metapneumovirus hMPV are non segmented negative strand viruses NNSV and are the leading causes of acute respiratory tract infections in infants worldwide In addition hRSV is a significant cause of disease in elderly populations and can often be fatal for patients with compromised immune systems Currently no vaccines are available and exis ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  3. Innovative Mitigation of Radiation Effects in Advanced Technology Nodes

    SBC: Reliable MicroSystems, LLC            Topic: DTRA16A003

    Establish a radiation-aware analysis capability in a commercial EDA design flow that will enable first-pass success in radiation-hardened by design (RHBD) for DoD ASICs in much the same way that existing EDA design suites ensure first pass functionality and performance success of complex ASICs destined for commercial applications. Layout-aware, calibrated single-event radiation models that captur ...

    STTR Phase I 2016 Department of DefenseDefense Threat Reduction Agency
  4. T SS needle protein inhibitors for the treatment of P aeruginosa infection

    SBC: MICROBIOTIX, INC.            Topic: NIAID

    DESCRIPTION provided by applicant The inability to treat many Gram negative bacterial infections effectively with existing antibiotics is a major medical crisis Pseudomonas aeruginosa is a prime example of clinical isolates from critically ill patients are resistant to three or more drugs The overall goal of this project is to address the critical medical need by a novel approach of iden ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government